Login / Signup

Immunothrombotic dysregulation in chagas disease and COVID-19: a comparative study of anticoagulation.

Laura Pérez-Campos MayoralMaría Teresa Hernández-HuertaDulce Papy-GarcíaDenis BarritaultEdgar ZentenoLuis Manuel Sánchez NavarroEduardo Pérez-Campos MayoralCarlos Alberto Matias CervantesMargarito Martínez CruzGabriel Mayoral AndradeMalaquías López CervantesGabriela Vázquez MartínezClaudia López SánchezSocorro Pina CansecoRuth Martínez CruzEduardo Pérez-Campos Mayoral
Published in: Molecular and cellular biochemistry (2021)
Chagas and COVID-19 are diseases caused by Trypanosoma cruzi and SARS-CoV-2, respectively. These diseases present very different etiological agents despite showing similarities such as susceptibility/risk factors, pathogen-associated molecular patterns (PAMPs), recognition of glycosaminoglycans, inflammation, vascular leakage hypercoagulability, microthrombosis, and endotheliopathy; all of which suggest, in part, treatments with similar principles. Here, both diseases are compared, focusing mainly on the characteristics related to dysregulated immunothrombosis. Given the in-depth investigation of molecules and mechanisms related to microthrombosis in COVID-19, it is necessary to reconsider a prompt treatment of Chagas disease with oral anticoagulants.
Keyphrases
  • sars cov
  • coronavirus disease
  • trypanosoma cruzi
  • respiratory syndrome coronavirus
  • atrial fibrillation
  • risk factors
  • oral anticoagulants
  • oxidative stress
  • venous thromboembolism
  • optical coherence tomography